Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

873.68 +0.56 (+0.06%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
What's Going On With Eli Lilly Shares Monday?
Eli Lilly and Co (NYSE: LLY) shares are moving higher Monday following the release of positive Phase 3 trial results for its weight loss drug, tirzepatide, marketed as Zepbound. 
Via Benzinga
Why ResMed Shares Are Trading Lower Monday
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatment of sleep apnea. 
Via Benzinga
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about... 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
(LLY) - Analyzing Eli Lilly and Co's Short Interest
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today
Via Benzinga
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today. 
Via InvestorPlace
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
Eli Lilly tested its weight-loss drug in people with obesity suffering from sleep apnea events. 
Via Investor's Business Daily
Eli Lilly's Zepbound For Weight Loss Shows Disease Resolution In Obese Sleep Apnea Patients, Lays Further Groundwork For Label Expansion
Eli Lilly's phase 3 SURMOUNT-OSA trials show tirzepatide injection significantly reduces apnea events in adults with obesity and moderate-to-severe obstructive sleep apnea. FDA decision expected by end... 
Via Benzinga
Exposures Product Safety
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Biotech Stocks to Buy Now: June 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
Weight loss drug manufacturers Novo Nordisk and Eli Lilly are being challenged in court. The companies are accused of failing to properly warn patients about associated risks. 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide. 
Via Benzinga
Hype Busters: 3 Overvalued Stocks Ready for a Reality Check
Discover three overvalued stocks that have completely lost touch with reality, with growth assumptions destined for disappointment. 
Via InvestorPlace
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media. 
Via Benzinga
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Lilly is a good pick...but this one is better. 
Via The Motley Fool
Eli Lilly Has a New Drug That Could Push the Stock Higher
The Alzheimer’s treatment market is large and expected to grow. 
Via The Motley Fool
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024
Investors hunting for stocks that will provide big gains should consider these top-rated growth stocks that have upside potential. 
Via InvestorPlace
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
The company's promising Alzheimer's drug could soon obtain approval from regulators. 
Via The Motley Fool
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of... 
Via Benzinga
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors. 
Via MarketBeat
Exposures Product Safety
Eli Lilly Stock Analysis: Buy, Hold, or Sell?
Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines. 
Via The Motley Fool
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009. 
Via Investor's Business Daily
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.